Analysis of circulating tumour DNA in paired plasma and sputum samples of EGFR-mutated NSCLC patients

被引：0
|
作者：
Grech, C. [1 ]
Hackner, K. [2 ]
Strieder, M. [2 ]
Buder, A. [1 ]
Hochmair, M. J. [3 ,4 ]
Filipits, M. [1 ]
Errhalt, P. [2 ]
机构：
[1] Med Univ Vienna, Ctr Comprehens Canc, Dept Med 1, Inst Canc Res, Vienna, Austria
[2] Karl Landsteiner Univ Hlth Sci, Univ Hosp Krems, Dept Pneumol, Krems, Austria
[3] Otto Wagner Hosp, Dept Resp & Crit Care Med, Vienna, Austria
[4] Otto Wagner Hosp, Ludwig Boltzmann Inst COPD & Resp Epidemiol, Vienna, Austria
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1417P
引用
收藏
页码：578 / 578
页数：1
相关论文
共 50 条
  • [41] Outcomes of surgery and subsequent therapy for central nervous system oligoprogression in EGFR-mutated NSCLC patients
    Perng, Pang-Shuo
    Hsu, Heng-Juei
    Lee, Jung-Shun
    Wang, Liang-Chao
    Huang, Chih-Yuan
    Tien, Chih-Hao
    Lai, Yu-Hsuan
    Su, Po-Lan
    Hsu, Hao-Hsiang
    Chen, Liang-Yi
    Lee, Po-Hsuan
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2023, 21 (01)
  • [42] Circulating tumour DNA: A new biomarker to monitor resistance in NSCLC patients treated with EGFR-TKIs
    Diao, Zhenli
    Han, Yanxi
    Zhang, Rui
    Li, Jinming
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2020, 1873 (02):
  • [43] RELAYþ: Exploratory Study of Ramucirumab Plus Gefitinib in Untreated Patients With EGFR-Mutated Metastatic NSCLC
    Nishio, Makoto
    Nishio, Kazuto
    Reck, Martin
    Garon, Edward B.
    Imamura, Fumio
    Kawaguchi, Tomoya
    Yamaguchi, Hiroyuki
    Ikeda, Satoshi
    Hirano, Katsuya
    Visseren-Grul, Carla
    Ceccarelli, Matteo
    Wijayawardana, Sameera R.
    Zimmermann, Annamaria
    Matsui, Tomok
    Enatsu, Sotaro
    Nakagawa, Kazuhiko
    JTO CLINICAL AND RESEARCH REPORTS, 2022, 3 (04):
  • [44] Hematological parameters in EGFR-mutated advanced NSCLC patients treated with TKIs: predicting survival and toxicity
    Jokic, Vera
    Savic-Vujovic, Katarina
    Spasic, Jelena
    Stanic, Nemanja
    Marinkovic, Mladen
    Radosavljevic, Davorin
    Cavic, Milena
    EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (06) : 673 - 679
  • [45] Outcomes of surgery and subsequent therapy for central nervous system oligoprogression in EGFR-mutated NSCLC patients
    Pang-Shuo Perng
    Heng-Juei Hsu
    Jung-Shun Lee
    Liang-Chao Wang
    Chih-Yuan Huang
    Chih-Hao Tien
    Yu-Hsuan Lai
    Po-Lan Su
    Hao-Hsiang Hsu
    Liang-Yi Chen
    Po-Hsuan Lee
    World Journal of Surgical Oncology, 21
  • [46] Neoadjuvant Osimertinib with/without Chemotherapy versus Chemotherapy in Patients with EGFR-mutated resectable NSCLC: NeoADAURA
    Griesinger, F.
    Tsuboi, M.
    Weder, W.
    Escriu, C.
    Blakely, C.
    He, J.
    Dacic, S.
    Yatabe, Y.
    Zeng, L.
    Walding, A.
    Chaft, J.
    PNEUMOLOGIE, 2021, 75 : S6 - S7
  • [47] Gefitinib and Pemetrexed Improve Survival in EGFR-Mutated NSCLC - Tarring all Patients With the Same Brush?
    Arulananda, Surein
    John, Thomas
    JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (01) : 12 - 14
  • [48] A Study of Aumolertinib Monotherapy or Combination Treated EGFR-mutated NSCLC Patients with Symptomatic Brain Metastases
    Zhang, X.
    Zhang, M.
    Du, X.
    Zhang, G.
    Niu, Y.
    Wei, C.
    Guo, L.
    Shi, C.
    Wang, H.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S660 - S660
  • [49] Subtyping EGFR-mutated NSCLC Patients with Adjuvant TKIs or Chemotherapy Using Deep Radiomic Signatures
    Qi, Y. -F.
    Li, J.
    Qiu, Z. -B.
    Wu, Y. -L.
    Zhang, X.
    Zhong, W. -Z.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S565 - S566
  • [50] A Retrospective Comparison of Survival Outcomes in EGFR-mutated, NSCLC Patients on Osimertinib plus /- Brain Metastases
    Litt, I.
    Gibson, A.
    Dean, M.
    Elegbede, A.
    Bebb, G.
    Cheung, W.
    Pabani, A.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S232 - S232
12345